A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
The purpose of this study is to evaluate how abemaciclib interacts with a drug mixture containing caffeine, warfarin, dextromethorphan, and midazolam and how this interaction affects blood levels in the body.
Your participation could last up to 4 months or longer if you continue to take the study drug.
Key Participation Requirements
All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria
Participants must have a diagnosis of cancer that is advanced and/or metastatic and is confirmed by histology or cytology
Participants must discontinue all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, cancer-related hormone therapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug
Participants must not have history or presence of significant bleeding disorders
Participants must not have known active uncontrolled or symptomatic CNS metastases
Participants must not have a primary liver tumor
Participants must not have lymphoma or leukemia